Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford
GlycoSciences and marketed by Actelion and is used primarily to treat type I ...
Lancet Neurol. 2007 Sep;6(9):765-72. Miglustat for treatment of Niemann-Pick C
disease: a randomised controlled study. Patterson MC(1), Vecchio D, Prady H, ...
Apr 15, 2016 ... Miglustat is used to treat Gaucher's disease (a condition in which a certain fatty
substance is not broken down normally in the body and instead ...
Jun 13, 2005 ... Miglustat is a drug used to treat Gaucher disease. It inhibits the enzyme
glucosylceramide synthase, an essential enzyme for the synthesis of ...
Zavesca (miglustat) reduces the formation of a certain protein in the body in
people with type 1 Gaucher disease. Gaucher disease is a genetic condition in ...
Home · Find medicine; Human medicines. Zavesca. miglustat. Email; Print; Help.
Share. About; Authorisation details; Product information; Assessment history ...
Each capsule contains 100 mg miglustat. For the full list of excipients, see section
6.1. 3. PHARMACEUTICAL FORM. Hard capsule. White capsules with “OGT ...
Miglustat reduces the biosynthesis of glucosylceramide from ceramide through
the inhibition of the enzyme glucosylceramide synthase. Glucosylceramide is the
Oct 20, 2015 ... Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics
(SPC) by Actelion Pharmaceuticals UK Ltd.